$101,254,662

Ongoing support for Ohio State University's Comprehensive Cancer Center research programs, with a 2026 obligation increment on a project that began in 1997.

Nearly three-decade investment in cancer research infrastructure and discovery at a major academic medical center; sustained federal commitment to translational oncology.

Supports demand for laboratory equipment, reagents, sequencing services, and specialized biomedical instrumentation from research suppliers.

U.S. cancer research leadership depends on sustained NIH funding to maintain competitive advantage in precision oncology and immunotherapy innovation.